You are here: Industry Insights > Sandoz

News List

Novartis to Divest Sandoz US Dermatology Business to Aurobindo americanpharmaceuticalreview
September 07, 2018
Novartis has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA, for $0.9 billion of cash plus $0.1 billion of potential earn-outs.
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo worldpharmanews
September 07, 2018
Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billi
Novartis and Sandoz withdraw medicines from US over packaging concerns pharmaceutical-technology
July 12, 2018
Novartis and its affiliated Sandoz division have voluntarily recalled certain lots of 12 blister packs of medicines from the US market as the packaging did not meet US federal requirements.
Sandoz becomes first Canadian pharmaceutical company to enter medical cannabis field pharmaceutical-technology
June 28, 2018
Subsidiary of Sandoz International, Sandoz Canada, has finalised its alliance with Health Canada-licensed medical cannabis producer Tilray to improve Canadians’ access to high-quality, non-combustible medical cannabis products. This makes it the first Can
Sandoz US woes continue with biosimilar rejection pharmafile
May 04, 2018
In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – with sales of the generics unit down by 18%.
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA worldpharmanews
January 17, 2018
Sandos, a global leader in Novartis Pharmaceuticals and Biosimilars, announced today that the U.S. Food and Drug Administration (FDA) has accepted the BLA for Biologics Licenses submitted under section 351 (k)
EU regulators to review Sandoz’ Neulasta biosimilar pharmatimes
October 31, 2017
The European Medicines Agency has accepted for review Novartis unit Sandoz’ biosimilar of Amgen’s Neulasta.
Sandoz proposed biosimilar pegfilgrastim accepted by EMA europeanpharmaceuticalreview
October 30, 2017
Sandoz has announced that its biosimilar pegfilgrastim has been accepted by the EMA for regulatory review…
Sandoz to improve treatment access to children with cancer in four developing nations pharmaceutical-technology
July 31, 2017
Novartis Group division Sandoz has expanded its partnership with UK-based charity World Child Cancer to improve access to treatment, as well as optimise survival outcomes for children suffering from cancer in four developing nations.
Sandoz expands partnership with World Child Cancer biospectrumasia
July 27, 2017
The expanded partnership highlights Sandoz's commitment to work together with key stakeholders worldwide to expand access to healthcare.

Previous page 1 2 3 4 5 6 7 8 Next page